Mutations in KRAS and other oncogenes (such as MYC) and tumor suppressors (TP53, RB and PTEN) have been identified as the principal drivers of PDAC reprogramming cellular metabolism towards enhanced cancer growth [270]. This evidence concerns the gene KRAS and cancer.